MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026GlobeNewsWire • Thursday
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga • 10/19/26
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management MoleculeBenzinga • 09/09/26
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight ManagementGlobeNewsWire • 09/09/26
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
MannKind Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/26
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF TranscriptSeeking Alpha • 07/30/26
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPFGlobeNewsWire • 07/29/26
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026GlobeNewsWire • 07/28/26
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney DiseaseBenzinga • 07/24/26
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload TranscriptSeeking Alpha • 07/24/26
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney DiseaseGlobeNewsWire • 07/24/26